HeartBeam Snags New Patent For 12-Lead ECG Smartwatch-Based Monitor To Detect Heart Attacks

  • HeartBeam Inc BEAT announced that its patent for a 12-lead electrocardiogram (ECG) smartwatch-based monitor intended to detect heart attacks and complex cardiac arrhythmias was allowed by the United States Patent and Trademark Office (USPTO). 
  • The company says that currently available wearables cannot provide a 12-lead ECG for heart attack detection, complex arrhythmia monitoring, or other cardiac disorders.
  •  HeartBeam's latest patent further expands on the company's anytime, anywhere capabilities.
  • "The breakthrough inventions protected by this patent enable our proprietary 3D ECG technology to be built into a smartwatch, eliminating the need for a dedicated ECG device while offering a 12-lead ECG capability enabling heart attack and complex arrhythmia detection," said HeartBeam CEO and Founder Branislav Vajdic.
  • Recently, HeartBeam shares jumped 75% after its patent for a 12-lead electrocardiogram patch monitor intended to detect acute coronary syndrome and cardiac arrhythmia, which the USPTO issued.
  • Price Action: BEAT shares are down 1.40% at $3.65 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!